June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Characterizing anti-VEGF treatment patterns for neovascular age-related macular degeneration in the United Kingdom
Author Affiliations & Notes
  • Mishank Jain
    Western Eye Hospital, London, London, United Kingdom
  • Ronald Cantrell
    Genentech Inc, South San Francisco, California, United States
  • Jaya Devi Chidambaram
    Roche Products Ltd, Welwyn Garden City, Hertfordshire, United Kingdom
  • Davneet Judge
    Roche Products Ltd, Welwyn Garden City, Hertfordshire, United Kingdom
  • Melanie Dodds
    Medisoft Limited, Leeds, United Kingdom
  • Sarah McGrory
    Medisoft Limited, Leeds, United Kingdom
  • Clare Bailey
    Bristol Eye Hospital, Bristol, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships   Mishank Jain Roche, Code C (Consultant/Contractor); Ronald Cantrell Genentech, Inc., Code E (Employment), Roche, Code I (Personal Financial Interest); Jaya Chidambaram Roche, Code E (Employment); Davneet Judge Roche, Code E (Employment); Melanie Dodds Medisoft Limited, Code E (Employment); Sarah McGrory Medisoft Limited, Code E (Employment); Clare Bailey Novartis, Bayer, Roche, Alimera Sciences, Janssen, Boehringer Ingelheim, Code C (Consultant/Contractor)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1315 – F0149. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mishank Jain, Ronald Cantrell, Jaya Devi Chidambaram, Davneet Judge, Melanie Dodds, Sarah McGrory, Clare Bailey; Characterizing anti-VEGF treatment patterns for neovascular age-related macular degeneration in the United Kingdom. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1315 – F0149.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Anti–vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD), the leading cause of blindness and visual impairment in the United Kingdom (UK), require frequent intravitreal injections and monitoring. These can pose a substantial burden to patients, caregivers, and health care professionals. This study of routine clinical practice characterized long-term anti-VEGF treatment patterns for nAMD in the UK.

Methods : This was a retrospective analysis of a multicenter electronic medical record (EMR) database that contains data from 9 UK National Health Service ophthalmology sites. A deidentified dataset was constructed from anonymized Medisoft EMR of patients with initial nAMD diagnosis in ≥ 1 eye between January 1, 2014, and December 31, 2018, ≥ 1 anti-VEGF injection (ranibizumab, aflibercept, or bevacizumab), and ≥ 12 months of follow-up. Results are reported by anti-VEGF agent initiated; patients were able to switch anti-VEGF agents.

Results : A cohort of 10,971 patients was analyzed (aflibercept, n = 4908; ranibizumab, n = 5699; bevacizumab, n = 364 [not reported]). In year 1, for patients initiating either aflibercept or ranibizumab, the mean (SD) interval between consecutive injections was 48.4 (21.8) and 46.8 (26.4) days, respectively, and the mean (SD) number of treatment visits was 7.3 (2.5) and 6.4 (2.8), respectively. For aflibercept, the mean (SD; n) treatment interval was 59.0 (27.4; 3523) days in year 2 and 56.6 (26.5; 1812), 55.2 (26.2; 899), and 52.3 (24.6; 409) days in years 3−5, respectively. For ranibizumab, these were 59.9 (29.5; 3128) days in year 2, and 58.7 (27.6; 1791), 58.6 (26.9; 1032), and 56.6 (26.4; 530) days in years 3−5, respectively. The mean (SD) number of treatment visits was also similar for years 2−5 (aflibercept: 5.3 [3.1], 5.5 [3.4], 5.7 [3.5], 5.7 [3.7]); ranibizumab: 5.3 [2.9], 5.5 [2.9], 5.2 [2.9], 4.9 [2.9]) for patients with available data.

Conclusions : Overall, treatment patterns were consistent throughout the follow-up period and data from years 2−5 suggest that patients initiating ranibizumab or aflibercept maintained relatively stable treatment intervals, receiving anti-VEGF injections approximately every 8 weeks.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×